Edmond DE Rothschild Holding S.A. Makes New Investment in AxoGen, Inc. $AXGN

Edmond DE Rothschild Holding S.A. purchased a new position in shares of AxoGen, Inc. (NASDAQ:AXGN) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 31,800 shares of the medical equipment provider’s stock, valued at approximately $1,469,000.

A number of other institutional investors have also modified their holdings of the company. Stephens Investment Management Group LLC acquired a new stake in shares of AxoGen during the 4th quarter worth about $5,043,000. Lisanti Capital Growth LLC acquired a new stake in AxoGen during the second quarter worth approximately $4,183,000. Legato Capital Management LLC purchased a new stake in shares of AxoGen during the 4th quarter worth approximately $1,323,000. SummitTX Capital L.P. purchased a new stake in shares of AxoGen during the 1st quarter worth approximately $7,769,000. Finally, Bessemer Group Inc. boosted its holdings in shares of AxoGen by 41.9% in the 1st quarter. Bessemer Group Inc. now owns 660,553 shares of the medical equipment provider’s stock valued at $21,885,000 after buying an additional 194,949 shares in the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AXGN has been the topic of several research analyst reports. Citigroup reiterated a “market outperform” rating on shares of AxoGen in a research note on Thursday, July 30th. Wells Fargo & Company lifted their target price on AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Citizens Jmp boosted their target price on AxoGen from $50.00 to $55.00 and gave the company a “market outperform” rating in a report on Thursday, July 30th. Truist Financial set a $55.00 target price on AxoGen in a research report on Thursday, July 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $55.00 price target on shares of AxoGen in a research report on Wednesday, July 29th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $51.00.

AxoGen Stock Performance

NASDAQ:AXGN opened at $46.44 on Friday. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -68.29 and a beta of 1.11. The firm’s fifty day moving average price is $43.96 and its 200 day moving average price is $38.88. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.60 and a quick ratio of 5.04. AxoGen, Inc. has a 1-year low of $13.64 and a 1-year high of $50.66.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.12. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. The firm had revenue of $69.73 million during the quarter, compared to analysts’ expectations of $67.10 million. On average, sell-side analysts expect that AxoGen, Inc. will post -0.45 EPS for the current year.

Insider Transactions at AxoGen

In other news, Director Kathy Johnson Weiler sold 14,150 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $45.30, for a total transaction of $640,995.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc A. Began sold 67,500 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the completion of the sale, the executive vice president owned 50,135 shares of the company’s stock, valued at $2,373,390.90. This trade represents a 57.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 95,003 shares of company stock valued at $4,482,997 in the last ninety days. 2.44% of the stock is currently owned by company insiders.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.